Geron (GERN) Competitors $1.30 -0.09 (-6.47%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.32 +0.02 (+1.62%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, MNKD, INVA, NVAX, and OPKShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies MannKind Innoviva Novavax OPKO Health Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Is GERN or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Geron's net margin of -53.52%. Alkermes' return on equity of 24.86% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-53.52% -30.79% -16.17% Alkermes 23.15%24.86%17.14% Does the media refer more to GERN or ALKS? In the previous week, Geron had 3 more articles in the media than Alkermes. MarketBeat recorded 19 mentions for Geron and 16 mentions for Alkermes. Alkermes' average media sentiment score of 1.28 beat Geron's score of 0.35 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 5 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alkermes 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GERN or ALKS? Geron presently has a consensus target price of $4.19, suggesting a potential upside of 222.12%. Alkermes has a consensus target price of $41.08, suggesting a potential upside of 54.51%. Given Geron's higher possible upside, research analysts clearly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more risk and volatility, GERN or ALKS? Geron has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Which has preferable valuation & earnings, GERN or ALKS? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M10.75-$174.57M-$0.21-6.19Alkermes$1.51B2.92$367.07M$2.0812.78 Do insiders & institutionals hold more shares of GERN or ALKS? 73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 7.4% of Geron shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAlkermes beats Geron on 11 of the 16 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$885.32M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-10.0017.9729.9425.14Price / Sales10.75262.51398.9486.71Price / CashN/A41.8335.9458.58Price / Book2.837.238.105.59Net Income-$174.57M-$54.43M$3.26B$265.48M7 Day Performance11.11%0.22%0.68%1.22%1 Month Performance-6.47%5.59%2.46%0.39%1 Year Performance-71.74%9.98%27.69%23.47% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.14 of 5 stars$1.30-6.5%$4.19+222.1%-71.5%$885.32M$76.99M-10.00229Trending NewsEarnings ReportALKSAlkermes4.7831 of 5 stars$26.49-5.2%$41.08+55.1%+0.6%$4.61B$1.56B12.741,800Positive NewsLGNDLigand Pharmaceuticals3.5201 of 5 stars$131.58-2.7%$150.00+14.0%+56.8%$2.61B$167.13M-18.4880FOLDAmicus Therapeutics4.1118 of 5 stars$5.99-2.3%$16.22+170.8%-32.1%$1.89B$528.29M-66.55480High Trading VolumeBCRXBioCryst Pharmaceuticals4.1685 of 5 stars$8.14-1.0%$16.70+105.2%+12.2%$1.72B$450.71M-31.31530Earnings ReportAnalyst RevisionCLDXCelldex Therapeutics1.3835 of 5 stars$21.98-3.6%$50.11+128.0%-33.8%$1.51B$7.02M-8.14150Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionDVAXDynavax Technologies4.31 of 5 stars$10.98-1.7%$24.00+118.6%+2.9%$1.34B$277.25M-21.12350News CoverageEarnings ReportMNKDMannKind3.428 of 5 stars$3.78-2.3%$9.86+160.8%-31.5%$1.18B$285.50M37.80400Trending NewsEarnings ReportAnalyst ForecastGap UpINVAInnoviva4.3078 of 5 stars$18.17-1.4%$40.33+122.0%+1.8%$1.16B$358.71M-17.99100Positive NewsEarnings ReportNVAXNovavax4.7103 of 5 stars$6.65-2.9%$15.86+138.5%-18.0%$1.11B$682.16M2.511,990Trending NewsEarnings ReportOPKOPKO Health4.1325 of 5 stars$1.28-4.5%$2.75+114.8%-3.9%$1.06B$713.10M-18.282,997News CoverageAnalyst Revision Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors BCRX Competitors CLDX Competitors DVAX Competitors MNKD Competitors INVA Competitors NVAX Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
